Background: Mycoplasma pneumoniae is a common pathogen causing pneumonia;
| INTRODUC TI ON
Mycoplasma pneumoniae is one of the most common pathogens in community-acquired pneumonia (CAP), determined in 41.1% of pediatric and 13.0% of adult CAP cases in Japan. 1, 2 Most available antimicrobial agents, especially beta-lactam agents, 3 are not effective against M. pneumoniae; 4 thus, risk factors and clinical manifestations have been intensively investigated. Till date, school-aged children and adolescents, 3 persistent cough, 5 vomiting or diarrhea, 6 and autumn or winter outbreak 7 have been identified as factors associated with M. pneumoniae infections.
Macrolides are used as the first-line therapy for the treatment of M. pneumoniae infections, especially in children, owing to their high efficacy 8 and safety profile. 9, 10 However, macrolide resistance of M. pneumoniae, which is acquired by mutations of the ribosomal target of macrolides, 11 has been spreading rapidly and widely since 2000, 12 resulting in enhanced disease severity with increased complications. 13, 14 The prevalence of macrolide-resistant M. pneumoniae is 23.3%-100% in East Asian regions, 3.5%-13.2% in North America, and below 10% in European countries, except Italy, which has a higher rate of 26%. 11 Tanaka et al 15 
| MATERIAL S AND ME THODS

| Definition of pneumonia and evaluation of data
The diagnosis of pneumonia was made based on radiological findings and clinical symptoms compatible with pneumonia, without other causes attributed to abnormal radiological findings. 16, 17 The radiological finding was reviewed by two independent physicians, and only cases diagnosed as pneumonia by both physicians were included as pneumonia cases. Discordant cases were further reviewed by a board-certified radiologist to make a final diagnosis.
For background data, we collected information on age, gender, 
| RE SULTS
| Monthly trends in the number of cases infected with M. pneumoniae harboring MRM
We examined 1307 individual cases for the determination of M. pneumoniae using the GENECUBE system and GENECUBE Mycoplasma detection kit between May 2016 and April 2017; M. pneumoniae was identified in a total of 384 cases. Of these, one case was excluded from our study because colonization was highly suspected.
Therefore, we included a total of 383 M. pneumoniae infection cases in the final analysis. Table 1 summarizes the demographic data of all 383 M. pneumoniae infection cases. The median age was 8.0 years (47.8% female), and a large majority of cases (>80%) was pediatric. Asthma was the most common comorbidity identified (11.2%). Antimicrobials were prescribed for over half of the cases before evaluation, with the majority prescribed macrolides (29.2%), and the median duration from symptom onset to evaluation was 7.0 days. Among the observed clinical signs and symptoms, fever ≥38°C was the most frequent, followed by sputum or productive cough, severe cough, rhinorrhea, crackles auscultated upon chest examination, diarrhea, skin rashes, and hypoxia. The median WBC count and CRP values were 7100/ μL and 2.20 mg/dL, respectively. Pneumonia was the most common diagnosis and accounted for 275 cases (71.8%). There was no mortality in any of the cases included in this study, whereas 23.0% of the cases required hospitalization on the day of or before evaluation.
| Demographic data of all cases infected with M. pneumoniae
| Clinical characteristics of pneumonia caused by M. pneumoniae with MRM
Among the 275 pneumonia cases determined to be caused by M. pneumoniae, 222 were pediatric and 53 were adult cases.
Comparison of clinical characteristics of pediatric and adult pneumonia cases, with and without MRM, is shown in Table 2 and Table 3, respectively.
In the 222 pediatric cases, MRM was found in 145 (65.3%) cases.
As shown in Table 2 , neither the median age nor gender distribution significantly differed between the two groups. Fewer comorbidities were identified among the cases with MRM (7.6% vs 22.1%, P = 0.003), whereas these cases showed a higher frequency of history of antimicrobial use, especially macrolide use (43.4% vs 13.0%, The characteristics of 53 adult M. pneumoniae pneumonia cases are presented in Table 3 , including 26 cases with MRM (49.1%).
There was no significant difference between the cases with and without MRM in terms of age, gender distribution, presence of comorbidities, and any clinical signs and symptoms. The significant variables in univariate analyses were the use of macrolides before 
| D ISCUSS I ON
In this study, we demonstrated a high variation in MRM determination to be influenced by macrolide resistance. 22 Consistent with previous studies, our results indicated that clinical signs and symptoms were almost identical between pneumonia cases with and without MRM, 21, 22 except for the macrolide prescription rate before evaluation. 23 The higher macrolide prescription rate before evaluation, observed in MRM pneumonia cases, could be explained by the poor clinical response to the initial treatment, which may contribute to increased hospital visits.
Collecting the updated data of MRM determination rates among cases of M. pneumoniae infections may help to predict macrolide shown to vary from 50% to 93% across the seven districts of Japan, 24 as well as among areas in the same prefecture ranging from 0 to 100% (Hokkaido). 23 In this study, we employed the GENECUBE system and Macrolides and tetracyclines have an excellent therapeutic effect against M. pneumoniae, 26 and defervescence is usually achieved within 48-72 hours in successful M. pneumoniae pneumonia cases. 27 However, tetracyclines are contraindicated in children less than 8 years of age, who are at a high risk of M. pneumoniae infections. Tosufloxacin is effective against both macrolide-susceptible and macrolide-resistant strains, although its weak bactericidal effect limits its therapeutic efficacy. 27 Taken together, especially in pediatric patients, first-line treatment for macrolide-susceptible M. pneumoniae pneumonia should be macrolides, whereas tetracycline or tosufloxacin should be preserved for macrolide-resistant M. pneumoniae pneumonia, and tetracycline is preferred choice for cases older than 8 years of age.
Excessive use of macrolides and quinolones for respiratory infections has been a major concern in Japan, 28 because of their possible association to high macrolide resistance rates among Streptococcus pneumoniae 29 and M. pneumoniae, 7 and increased quinolone resistance among Enterobacteriaceae. 30 Besides the reduction in antibiotic use, we consider that rapid diagnoses and early initiation of effec- as it could not be determined by the GENECUBE system and GENECUBE Mycoplasma detection kit. However, a previous study showed that mutations at site 2617 were rarely determined in Japan (0.3%), 15 and these mutations are also known to confer only weak resistance to macrolides. 31 Therefore, any undetermined mutations at site 2617 were considered to have a negligible impact on the general conclusions of our study. TA B L E 3 Factors associated with the determination of macrolide-resistant mutations among adult cases with Mycoplasma pneumoniae pneumonia research expenses for the quality evaluation of the GENECUBE and GENECUBE Mycoplasma systems.
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